Figure 5.

Reovirus-Initiated Anti-tumor Immunity Protects against Subsequent Tumor Challenge and Depends on CD4⁺ T Cells and NK Cells

(A) C57BL/6 mice who had demonstrated complete remission of their tumors following reovirus plus antibody therapy were subsequently further challenged 63 days after initial viral therapy with 5 × 10⁶ TRAMP-C2 cells. A control group of naive C57BL/6 mice also received 5 × 10⁶ TRAMP-C2 cells. Both groups of mice were monitored for tumor growth. (B) C57BL/6 mice were treated as described in Figure 4 with or without depleting antibodies for CD4⁺, CD8⁺, or NK cells and monitored for tumor growth. The statistical significance of the intergroup comparisons of tumor volumes was determined using a two-way ANOVA. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.